---
title: Investigational Treatment Options for PAD, CLTI and Vascular Dementia
description: Learn about investigational clinical research for PAD, CLTI, cardiovascular ischemia and vascular dementia, and request a clinical evaluation.
---
[](https://hemostemix.com?hsLang=en)
- [Patient Information](https://hemostemix.com/investigational-treatment-options)
- [Physician Information](https://hemostemix.com/physicians)
- ACP-01
Show submenu for ACP-01
- [ACP-01](https://hemostemix.com/acp-autologous-stem-cell-therapy)
- [Clinical Research](https://hemostemix.com/clinical-research)
- Conditions
Show submenu for Conditions
- [Cardiovascular Ischemia & Angina](https://hemostemix.com/cardiovascular-ischemia-angina)
- [Chronic Limb Ischemia - CLTI](https://hemostemix.com/chronic-limb-threatening-ischemia)
- [Peripheral Arterial Disease- PAD](https://hemostemix.com/peripheral-arterial-disease-pad-and-peripheral-ischemia)
- [Vascular Dementia](https://hemostemix.com/vascular-dementia)
- [Wound Care](https://hemostemix.com/wound-care)
- [Events & Replays](https://hemostemix.com/events)
- Blog
Show submenu for Blog
- [Hemostemix Health Hub](https://hemostemix.com/health-hub-blog)
- [Hemostemix Video Library](https://hemostemix.com/videolibrary)
- [About](https://hemostemix.com/about)
- [Patient Information](https://hemostemix.com/investigational-treatment-options)
- [Physician Information](https://hemostemix.com/physicians)
- ACP-01
Show submenu for ACP-01
- [ACP-01](https://hemostemix.com/acp-autologous-stem-cell-therapy)
- [Clinical Research](https://hemostemix.com/clinical-research)
- Conditions
Show submenu for Conditions
- [Cardiovascular Ischemia & Angina](https://hemostemix.com/cardiovascular-ischemia-angina)
- [Chronic Limb Ischemia - CLTI](https://hemostemix.com/chronic-limb-threatening-ischemia)
- [Peripheral Arterial Disease- PAD](https://hemostemix.com/peripheral-arterial-disease-pad-and-peripheral-ischemia)
- [Vascular Dementia](https://hemostemix.com/vascular-dementia)
- [Wound Care](https://hemostemix.com/wound-care)
- [Events & Replays](https://hemostemix.com/events)
- Blog
Show submenu for Blog
- [Hemostemix Health Hub](https://hemostemix.com/health-hub-blog)
- [Hemostemix Video Library](https://hemostemix.com/videolibrary)
- [About](https://hemostemix.com/about)
[Investor Site](https://investors.hemostemix.com/?hsLang=en)
# Investigational Treatment Options for Advanced Vascular and Ischemic Conditions
## When standard treatment options are limited, individuals diagnosed with advanced peripheral arterial disease, chronic limb threatening ischemia, or vascular dementia may seek additional investigational approaches. ACP-01 is an autologous cell therapy evaluated in clinical research for select vascular and ischemic conditions.
## Understanding current treatment pathways is an important first step when exploring investigational options.
Schedule a Consultation
# Investigational Treatment Options for Advanced Vascular and Ischemic Conditions
## When standard treatment options are limited, individuals diagnosed with advanced peripheral arterial disease, chronic limb threatening ischemia, or vascular dementia may seek additional investigational approaches. ACP-01 is an autologous cell therapy evaluated in clinical research for select vascular and ischemic conditions.
## Understanding current treatment pathways is an important first step when exploring investigational options.
Schedule A Consultation
## **When Standard Treatments Are No Longer Enough**
Patients diagnosed with advanced peripheral arterial disease (PAD), chronic limb threatening ischemia (CLTI), refractory angina, ischemic cardiomyopathy, or vascular-related cognitive decline often pursue multiple medical and surgical therapies.
In some cases, symptoms persist despite intervention. Circulation remains compromised. Pain continues. Wounds do not heal. Functional decline progresses.
When conventional therapies are no longer viable or have not produced meaningful improvement, patients may begin exploring structured investigational clinical research options.
Hemostemix is evaluating ACP-01, an investigational autologous angiogenic cell therapy, within controlled clinical research settings.
ACP-01 is not FDA approved and remains investigational.
## **When Standard Treatments Are No Longer Enough**
Patients diagnosed with advanced peripheral arterial disease (PAD), chronic limb threatening ischemia (CLTI), refractory angina, ischemic cardiomyopathy, or vascular-related cognitive decline often pursue multiple medical and surgical therapies.
In some cases, symptoms persist despite intervention. Circulation remains compromised. Pain continues. Wounds do not heal. Functional decline progresses.
When conventional therapies are no longer viable or have not produced meaningful improvement, patients may begin exploring structured investigational clinical research options.
Hemostemix is evaluating ACP-01, an investigational autologous angiogenic cell therapy, within controlled clinical research settings.
ACP-01 is not FDA approved and remains investigational.
## What “Investigational” Means
Investigational therapy refers to a product that is being studied in formal clinical research to evaluate safety and biological activity.
ACP-01 is derived from a patient’s own blood and processed using a standardized laboratory methodology to isolate angiogenic precursor cells. It is administered within defined research protocols under clinical oversight.
Investigational does not mean guaranteed results.
It does not replace standard medical care.
It is not a substitute for consultation with your treating physician.
It means the therapy is being studied under structured clinical development.
## What “Investigational” Means
Investigational therapy refers to a product that is being studied in formal clinical research to evaluate safety and biological activity.
ACP-01 is derived from a patient’s own blood and processed using a standardized laboratory methodology to isolate angiogenic precursor cells. It is administered within defined research protocols under clinical oversight.
Investigational does not mean guaranteed results.
It does not replace standard medical care.
It is not a substitute for consultation with your treating physician.
It means the therapy is being studied under structured clinical development.
## **Conditions Studied in Clinical Research**
ACP-01 has been evaluated in research settings involving patients with advanced ischemic disease, including:
## **Conditions Studied in Clinical Research**
ACP-01 has been evaluated in research settings involving patients with advanced ischemic disease, including:
###### Peripheral Arterial Disease (PAD)
A circulatory condition that reduces blood flow to the limbs and may lead to leg pain, non-healing wounds, or progressive tissue damage.
###### Chronic Limb Threatening Ischemia (CLTI)
An advanced stage of arterial disease associated with severe circulation impairment, rest pain, ulceration, and risk of tissue loss.
###### Cardiovascular Ischemia & Refractory Angina
Impaired coronary blood flow that may result in persistent chest discomfort, ischemic cardiomyopathy, or reduced cardiac function.
###### Vascular Dementia & Cognitive Decline
Cognitive impairment associated with reduced cerebral blood flow and vascular injury.
###### Non-Healing Wound Care
Chronic wounds that fail to close due to inadequate blood supply, often affecting the lower extremities in patients with advanced vascular disease.
###### Chronic Pain
Persistent pain linked to compromised microvascular circulation, commonly associated with advanced arterial insufficiency.
## Who Typically Seeks Investigational Research
People who explore investigational research are usually navigating long, exhausting medical journeys. They’re not chasing miracles. They’re trying to understand whether emerging science may offer a different path when standard care hasn’t been enough or is out of options.
**Patients Living With Progressive Ischemia**
Individuals facing chronic limb ischemia, critical limb ischemia, or other forms of reduced blood flow often look toward investigational options when symptoms continue to worsen. They want to understand whether research‑driven approaches might help protect mobility, independence, and daily function.
**Patients Who Have Reached the Limits of Standard Treatment**
Many people arrive after trying medications, wound care, lifestyle changes, and surgical interventions. When progress slows or complications increase, they begin searching for science‑based alternatives that work differently than what they’ve already experienced.
**Patients Seeking Clarity, Not Guarantees**
These patients are thoughtful, informed, and cautious. They want to understand the mechanism, the science, and the clinical oversight behind an investigational therapy. They’re not looking for promises, they’re looking for transparency, data, and a team that communicates clearly about what is known and what is still being studied.
Patients Hoping to Avoid Major Amputation
For individuals who have been told they may be approaching amputation, investigational research can feel like a way to explore every possible avenue. They want to know whether there are research‑based options that may be relevant to their condition before making life‑altering decisions.
Patients Hoping to Avoid Major Amputation
For individuals who have been told they may be approaching amputation, investigational research can feel like a way to explore every possible avenue. They want to know whether there are research‑based options that may be relevant to their condition before making life‑altering decisions.
Patients Looking for Hope That’s Grounded in Evidence
These individuals want to feel seen, heard, and supported. They’re searching for a research team that understands the emotional weight of ischemic disease and provides credible science, clinical oversight, and compassionate guidance, not hype.
Patients Looking for Hope That’s Grounded in Evidence
These individuals want to feel seen, heard, and supported. They’re searching for a research team that understands the emotional weight of ischemic disease and provides credible science, clinical oversight, and compassionate guidance, not hype.
## Take the Next Step Toward Clarity and Options
Living with chronic limb ischemia, or another reduced‑blood‑flow condition, can feel heavy, especially when symptoms progress or standard treatments stop helping. Many people reach this point simply wanting to understand what options might still exist.
Investigational research isn’t a guarantee. It’s a structured, science‑based way to see whether an emerging approach may be relevant to your condition. A consultation gives you space to talk with a team who understands ischemia, review what’s known and what’s still being studied, and get clear on what participation would involve.
**Why Patients Choose to Reach Out:**
- They want to understand every possible avenue before making life‑altering decisions
- They’re looking for a research team that communicates with honesty and compassion
- They want clarity, not guarantees, so they can make informed choices about their health
- It gives you the information you need to decide what's right for you.
Schedule A Consultation
## What to Expect
If you contact Hemostemix, our team will:
A clear explanation of the investigational therapy and its scientific basis
A review of your medical history to understand whether the research may be appropriate to explore
Transparent discussion about risks, unknowns, and what participation looks like
Space to ask questions, express concerns, and understand your options without pressure
There is no obligation to proceed.
ACP-01 is an investigational therapy evaluated in clinical research. Regulatory status may vary by jurisdiction.
## **Frequently Asked Questions**
## **Frequently Asked Questions**
###### What are treatment options for peripheral arterial disease?
Peripheral arterial disease treatment options include medication, supervised exercise therapy, angioplasty, stenting, and bypass surgery. In advanced cases where procedures are not possible, some individuals explore investigational therapies being studied in clinical research.
###### What happens when bypass surgery is not possible?
When bypass surgery or stenting is not feasible due to disease progression or medical risk, physicians may focus on symptom management and wound care. Some patients inquire about investigational treatment options under structured research protocols.
###### What is chronic limb threatening ischemia?
Chronic limb threatening ischemia is an advanced form of peripheral arterial disease characterized by severely reduced blood flow, rest pain, or non-healing wounds. It is a serious condition requiring physician oversight.
###### Is ACP-01 FDA approved?
ACP-01 is an investigational therapy evaluated in clinical research. Regulatory status may vary by jurisdiction.
###### Can investigational therapies be considered for vascular dementia?
Research continues to explore vascular-related cognitive conditions. Investigational therapies may be studied in defined patient populations under structured clinical protocols.
Disclaimer
IMPORTANT NOTICE
ACP-01 is an investigational therapy and has not been approved by the U.S. Food and Drug Administration. Information provided on this website is for educational purposes only and does not constitute medical advice. Nothing on this site is intended to promote or market an unapproved therapy. Patients should consult a qualified healthcare professional regarding diagnosis and treatment decisions.
FLORIDA NOTICE
This notice is provided in accordance with Florida law. One or more physicians referenced may perform stem cell therapies that have not been approved by the United States Food and Drug Administration. Patients are encouraged to consult with their primary care provider before undergoing any stem cell therapy.
[](https://hemostemix.com?hsLang=en)
Leave us a message
Follow Us
Copyright © 2026 Hemostemix, Inc
[Privacy Policy |](https://hemostemix.com/privacy-policy?hsLang=en) [Terms of Service](https://hemostemix.com/sms-terms-of-service?hsLang=en)